X4 Pharmaceuticals (XFOR) News Today $0.47 -0.01 (-1.33%) Closing price 04:00 PM EasternExtended Trading$0.47 +0.00 (+1.05%) As of 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period X4 and taiba rare announce distribution agreement for XolremdiFebruary 19 at 12:31 PM | markets.businessinsider.comX4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East CountriesFebruary 19 at 7:35 AM | globenewswire.comX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Short Interest Up 22.6% in JanuaryX4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) was the target of a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 16,610,000 shares, an increase of 22.6% from the January 15th total of 13,550,000 shares. Based on an average trading volume of 5,310,000 shares, the days-to-cover ratio is presently 3.1 days.February 16, 2025 | marketbeat.comX4 pharmaceuticals chief commercial officer Mark Baldry acquires $19,251 in stockFebruary 14, 2025 | msn.comAnalysts Offer Predictions for XFOR FY2027 EarningsFebruary 12, 2025 | americanbankingnews.comHC Wainwright Has Negative Estimate for XFOR FY2028 EarningsFebruary 11, 2025 | americanbankingnews.comHC Wainwright Cuts Earnings Estimates for X4 PharmaceuticalsX4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - Investment analysts at HC Wainwright reduced their FY2028 earnings per share estimates for shares of X4 Pharmaceuticals in a report released on Friday, February 7th. HC Wainwright analyst S. Ramakanth now expects that the company will post eaFebruary 10, 2025 | marketbeat.comXFOR FY2027 EPS Reduced by Brookline Capital ManagementX4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - Equities research analysts at Brookline Capital Management dropped their FY2027 earnings per share (EPS) estimates for shares of X4 Pharmaceuticals in a research report issued on Thursday, February 6th. Brookline Capital Management analyst L.February 10, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for X4 Pharmaceuticals (NASDAQ:XFOR)HC Wainwright reissued a "buy" rating and set a $1.50 price objective on shares of X4 Pharmaceuticals in a research report on Friday.February 7, 2025 | marketbeat.comOne year after drug approval, X4 Pharmaceuticals cuts staffFebruary 6, 2025 | bizjournals.comX4 Pharmaceuticals announces strategic restructuring, reduces headcount by 30%February 6, 2025 | markets.businessinsider.comX4 Pharmaceuticals To Axe 30% Of Overall Workforce, Stock Falls In Pre-MarketFebruary 6, 2025 | markets.businessinsider.comX4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic NeutropeniaFebruary 6, 2025 | globenewswire.comX4 said to see takeover approach from Italy’s Cheisi, Street Insider reportsJanuary 30, 2025 | markets.businessinsider.comX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) COO Sells $10,016.10 in StockJanuary 28, 2025 | insidertrades.comX4 Pharmaceuticals' chief medical officer sells $5,284 in stockJanuary 28, 2025 | msn.comInsider Selling: X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) COO Sells 22,258 Shares of StockX4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) COO Mary Dibiase sold 22,258 shares of the stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $0.45, for a total value of $10,016.10. Following the completion of the sale, the chief operating officer now owns 490,980 shares in the company, valued at approximately $220,941. The trade was a 4.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.January 27, 2025 | marketbeat.comMark Baldry Sells 29,159 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) StockX4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) insider Mark Baldry sold 29,159 shares of the stock in a transaction on Friday, January 24th. The shares were sold at an average price of $0.45, for a total value of $13,121.55. Following the completion of the sale, the insider now owns 94,123 shares in the company, valued at approximately $42,355.35. This trade represents a 23.65 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.January 27, 2025 | marketbeat.comX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) CFO Adam S. Mostafa Sells 74,773 SharesX4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) CFO Adam S. Mostafa sold 74,773 shares of the firm's stock in a transaction on Friday, January 24th. The shares were sold at an average price of $0.45, for a total value of $33,647.85. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.January 27, 2025 | marketbeat.comInsider Selling: X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) CEO Sells 76,473 Shares of StockX4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) CEO Paula Ragan sold 76,473 shares of the company's stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $0.45, for a total transaction of $34,412.85. Following the sale, the chief executive officer now directly owns 1,087,386 shares in the company, valued at approximately $489,323.70. The trade was a 6.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.January 27, 2025 | marketbeat.comX4 Pharmaceuticals CFO Mostafa Adam S. sells $33,946 in stockJanuary 27, 2025 | msn.comx4 Pharmaceuticals chief commercial officer sells $13,241 in stockJanuary 27, 2025 | msn.comX4 Pharmaceuticals announces EMA validation of MAA for mavorixaforJanuary 24, 2025 | markets.businessinsider.comX4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM SyndromeJanuary 24, 2025 | globenewswire.comCantor Fitzgerald Sticks to Its Buy Rating for X4 Pharmaceuticals (XFOR)January 16, 2025 | markets.businessinsider.comXFOR: Receives €28.5 Upfront for Licensing Agreement with Norgine…January 15, 2025 | msn.comBuy Rating for X4 Pharmaceuticals Driven by Strategic Partnership and Strong ValuationJanuary 14, 2025 | markets.businessinsider.comX4 Pharmaceuticals (NASDAQ:XFOR) Earns "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $1.50 target price on shares of X4 Pharmaceuticals in a research note on Tuesday.January 14, 2025 | marketbeat.comStifel Nicolaus Remains a Buy on X4 Pharmaceuticals (XFOR)January 14, 2025 | markets.businessinsider.comX4, Norgine enter exclusive licensing agreement for mavorixaforJanuary 13, 2025 | markets.businessinsider.comX4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New ZealandJanuary 13, 2025 | globenewswire.comBrokers Set Expectations for XFOR FY2024 EarningsX4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - Analysts at Brookline Capital Management cut their FY2024 EPS estimates for X4 Pharmaceuticals in a research report issued on Monday, January 6th. Brookline Capital Management analyst L. Cann now anticipates that the company will post earningJanuary 9, 2025 | marketbeat.comUnusually active option classes on open December 10thDecember 11, 2024 | markets.businessinsider.comX4 Pharmaceuticals to present on Phase 3 study of MavorixaforDecember 5, 2024 | markets.businessinsider.comX4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting & ExpositionDecember 4, 2024 | markets.businessinsider.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 3, 2024 | globenewswire.comB. Riley Expects Stronger Earnings for X4 PharmaceuticalsX4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - Equities research analysts at B. Riley raised their FY2024 earnings per share (EPS) estimates for X4 Pharmaceuticals in a research note issued to investors on Monday, November 18th. B. Riley analyst K. Patel now expects that the company willNovember 20, 2024 | marketbeat.comResearch Analysts Set Expectations for XFOR FY2024 EarningsX4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - Equities research analysts at HC Wainwright decreased their FY2024 EPS estimates for shares of X4 Pharmaceuticals in a research note issued on Thursday, November 14th. HC Wainwright analyst S. Ramakanth now anticipates that the company will eNovember 18, 2024 | marketbeat.comX4 Pharmaceuticals price target lowered to $1.50 from $5 at H.C. WainwrightNovember 14, 2024 | markets.businessinsider.comXFOR: Positive Results for Phase 2 Trial of Mavorixafor in Chronic Neutropenia…November 14, 2024 | msn.comX4 Pharmaceuticals Inc (XFOR) Q3 2024 Earnings Call Highlights: Strategic Engagement and ...November 14, 2024 | finance.yahoo.comX4 Pharmaceuticals Reports Positive Trial Results and ProgressNovember 14, 2024 | markets.businessinsider.comX4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare ConferenceNovember 14, 2024 | globenewswire.comX4 Pharmaceuticals price target lowered to $4 from $5 at StifelNovember 14, 2024 | markets.businessinsider.comX4 Pharmaceuticals, Inc. (XFOR) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comX4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 13, 2024 | markets.businessinsider.comX4 Pharmaceuticals Posts Wider Loss In Q3 - Quick FactsNovember 13, 2024 | markets.businessinsider.comX4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 13, 2024 | globenewswire.comX4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)November 13, 2024 | globenewswire.comX4 Pharmaceuticals (XFOR) to Release Earnings on WednesdayX4 Pharmaceuticals (NASDAQ:XFOR) will be releasing earnings before the market opens on Wednesday, November 13, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=639867)November 6, 2024 | marketbeat.com Get X4 Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter. Email Address XFOR Media Mentions By Week XFOR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. XFOR News Sentiment▼0.730.60▲Average Medical News Sentiment XFOR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. XFOR Articles This Week▼43▲XFOR Articles Average Week Get X4 Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ACB News Today TERN News Today FHTX News Today TSHA News Today CYRX News Today ANNX News Today CRVS News Today TRVI News Today CMPS News Today AQST News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:XFOR) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding X4 Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share X4 Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
